文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向FAP与PSMA的异双价制剂

Hetero-bivalent agents targeting FAP and PSMA.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-08-15

本研究开发了双靶向成纤维细胞活化蛋白α(FAP)和前列腺特异性膜抗原(PSMA)的诊疗一体化放射性药物,合成FP-L1与FP-L2并用64Cu标记;在多种肿瘤模型中进行PET/CT与生物分布研究,结果显示64Cu-FP-L1对FAP和PSMA具有高且特异的靶向性,药代动力学优于64Cu-FP-L2。

要点

  • 64Cu-FP-L1与64Cu-FP-L2对FAP和PSMA的抑制常数(Ki)均在纳摩尔范围。
  • U87模型中64Cu-FP-L1 2小时肿瘤摄取10.83 ± 1.02%ID/g,与64Cu-FAPI-04的9.53 ± 2.55%ID/g相当。
  • 64Cu-FP-L1在PSMA+PC3 PIP肿瘤2小时摄取12.06 ± 0.78%ID/g,24小时为10.51 ± 1.82%ID/g。

核心结论

  • 64Cu-FP-L1对FAP和PSMA表现出高且特异的肿瘤靶向性。
  • 该化合物可用于显像表达FAP、PSMA或两者兼有的肿瘤细胞表面或肿瘤微环境中的病灶。
  • FP-L1可较容易地转化为诊疗一体化药物,用于异质性肿瘤的管理。

研究设计与样本

  • 研究合成FP-L1和FP-L2两种连接FAP与PSMA结合药效团的小分子化合物,并用64Cu标记。
  • 体外测定FAP和PSMA的抑制常数(Ki),并在人胶质瘤(U87)、黑色素瘤(SK-MEL-24)、前列腺癌(PSMA+ PC3 PIP与PSMA- PC3 flu)及透明细胞肾细胞癌(PSMA+/PSMA- 786-O)细胞系中进行摄取实验与流式细胞术。
  • 使用U87、SK-MEL-24、PSMA+ PC3 PIP和PSMA+ 786-O异种移植模型及KPC胰腺癌基因工程小鼠模型进行定量PET/CT与组织生物分布研究。

主要发现

  • 64Cu-FP-L1和64Cu-FP-L2的放射化学产率> 98%,摩尔活度> 19 MBq/nmol。
  • 两种化合物对FAP和PSMA的Ki值均在纳摩尔范围。
  • PET显像与生物分布显示64Cu-FP-L1和64Cu-FP-L2对FAP和PSMA具有高且特异的靶向性。
  • 64Cu-FP-L1的药代动力学优于64Cu-FP-L2。
  • U87肿瘤模型注射后2小时,64Cu-FP-L1肿瘤摄取为10.83 ± 1.02%ID/g,与64Cu-FAPI-04的9.53 ± 2.55%ID/g相当;64Cu-FP-L1在48小时仍保持5.34 ± 0.29%ID/g的高滞留。

关键数值与推荐

  • 64Cu-FP-L1和64Cu-FP-L2放射化学产率> 98%,摩尔活度> 19 MBq/nmol。
  • 两种化合物对FAP和PSMA的Ki值均在纳摩尔范围。
  • U87模型2小时肿瘤摄取:64Cu-FP-L1 10.83 ± 1.02%ID/g vs 64Cu-FAPI-04 9.53 ± 2.55%ID/g。
  • U87模型48小时64Cu-FP-L1肿瘤滞留5.34 ± 0.29%ID/g。
  • PSMA+ PC3 PIP肿瘤摄取:64Cu-FP-L1 2小时12.06 ± 0.78%ID/g,24小时10.51 ± 1.82%ID/g。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We developed a theranostic radiopharmaceutical that engages two key cell surface proteases, fibroblast activation protein alpha (FAP) and prostate-specific membrane antigen (PSMA), each frequently overexpressed within the tumor microenvironment (TME). The latter is also expressed in most prostate tumor epithelium. To engage a broader spectrum of cancers for imaging and therapy, we conjugated small-molecule FAP and PSMA-targeting moieties using an optimized linker to provide 64Cu-labeled compounds. METHODS: We synthesized FP-L1 and FP-L2 using two linker constructs attaching the FAP and PSMA-binding pharmacophores. We determined in vitro inhibition constants (Ki) for FAP and PSMA. Cell uptake assays and flow cytometry were conducted in human glioma (U87), melanoma (SK-MEL-24), prostate cancer (PSMA + PC3 PIP and PSMA - PC3 flu), and clear cell renal cell carcinoma lines (PSMA + /PSMA - 786-O). Quantitative positron emission tomography/computed tomography (PET/CT) and tissue biodistribution studies were performed using U87, SK-MEL-24, PSMA + PC3 PIP, and PSMA + 786-O experimental xenograft models and the KPC genetically engineered mouse model of pancreatic cancer. RESULTS: 64Cu-FP-L1 and 64Cu-FP-L2 were produced in high radiochemical yields (> 98%) and molar activities (> 19 MBq/nmol). Ki values were in the nanomolar range for both FAP and PSMA. PET imaging and biodistribution studies revealed high and specific targeting of 64Cu-FP-L1 and 64Cu-FP-L2 for FAP and PSMA. 64Cu-FP-L1 displayed more favorable pharmacokinetics than 64Cu-FP-L2. In the U87 tumor model at 2 h post-injection, tumor uptake of 64Cu-FP-L1 (10.83 ± 1.02%ID/g) was comparable to 64Cu-FAPI-04 (9.53 ± 2.55%ID/g). 64Cu-FP-L1 demonstrated high retention 5.34 ± 0.29%ID/g at 48 h in U87 tumor. Additionally, 64Cu-FP-L1 showed high retention in PSMA + PC3 PIP tumor (12.06 ± 0.78%ID/g at 2 h and 10.51 ± 1.82%ID/g at 24 h). CONCLUSIONS: 64Cu-FP-L1 demonstrated high and specific tumor targeting of FAP and PSMA. This compound should enable imaging of lesions expressing FAP, PSMA, or both on the tumor cell surface or within the TME. FP-L1 can readily be converted into a theranostic for the management of heterogeneous tumors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Boinapally S, Lisok A, Lofland G, et al. Hetero-bivalent agents targeting FAP and PSMA. Eur J Nucl Med Mol Imaging. 2022. PMID: 35965291. doi:10.1007/s00259-022-05933-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。